Tekla Life Sciences Investors - Asset Resilience Ratio

Latest as of March 2025: 2.96%

Tekla Life Sciences Investors (HQL) has an Asset Resilience Ratio of 2.96% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Tekla Life Sciences Investors (HQL) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$12.16 Million
Cash + Short-term Investments

Total Assets

$411.34 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Tekla Life Sciences Investors's Asset Resilience Ratio has changed over time. See shareholders equity of Tekla Life Sciences Investors for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Tekla Life Sciences Investors's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HQL market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $12.16 Million 2.96%
Total Liquid Assets $12.16 Million 2.96%

Asset Resilience Insights

  • Limited Liquidity: Tekla Life Sciences Investors maintains only 2.96% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Tekla Life Sciences Investors Industry Peers by Asset Resilience Ratio

Compare Tekla Life Sciences Investors's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sprott Physical Gold Trust
TO:PHYS
Asset Management 99.96%
Sprott Physical Silver
TO:PSLV
Asset Management 99.90%
Sprott Physical Gold and Silver Trust
TO:CEF
Asset Management 99.91%
Argo Investments Ltd
AU:ARG
Asset Management 0.46%
Brederode SA
BR:BREB
Asset Management 0.01%
Norte Grande
SN:NORTEGRAN
Asset Management 0.00%
Highest Performances Holdings Inc.
NASDAQ:MAAS
Asset Management 13.56%
Metrics Master Income Trust
AU:MXT
Asset Management 0.14%

Annual Asset Resilience Ratio for Tekla Life Sciences Investors (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Tekla Life Sciences Investors.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-09-30 3.74% $17.23 Million $460.58 Million -0.04pp
2023-09-30 3.79% $15.24 Million $402.60 Million -4.16pp
2022-09-30 7.94% $32.94 Million $414.73 Million +4.73pp
2021-09-30 3.21% $17.17 Million $534.19 Million +2.19pp
2020-09-30 1.03% $4.97 Million $484.17 Million -2.08pp
2019-09-30 3.11% $12.03 Million $386.98 Million +3.11pp
2018-09-30 0.00% $-1.00 $478.47 Million 0.00pp
2017-09-30 0.00% $4.00 $468.33 Million -2.36pp
2016-09-30 2.36% $9.85 Million $417.63 Million --
pp = percentage points

About Tekla Life Sciences Investors

NYSE:HQL USA Asset Management
Market Cap
$524.49 Million
Market Cap Rank
#12506 Global
#2918 in USA
Share Price
$17.72
Change (1 day)
+0.97%
52-Week Range
$11.99 - $18.01
All Time High
$18.01
About

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more